The goal of the University of Iowa/Mayo Clinic Lymphoma SPORE (UI/MC Lymphoma SPORE) CareerDevelopment Program (CDP) is to develop knowledgeable, well-trained scientists experienced inmultidisciplinary research for future studies in translational lymphoma research. The provision of ampleopportunities for training and career enhancement is a top priority of the University of Iowa and Mayo Clinicscientific communities. The extensive research and training base available at these two institutions providesstrong support for the UI/MC Lymphoma SPORE CDP. The primary objectives of the CDP are to: (1) trainyoung investigators (senior postdoctoral fellows and young faculty) in translational, multidisciplinary clinical orbasic lymphoma research; (2) redirect established investigators to further lymphoma research; and (3)collaborate with investigators from other institutions who are interested in pursuing a research career intranslational lymphoma research. During the initial funding period 6 young investigators received awards.Their work has led to the discovery of novel translocations, potential new methods of antigen presentation,and new treatments that are now being tested in clinical trials. During the next funding period, the UI/MCLymphoma SPORE will maintain: (1) a stringent candidate selection system; (2) comprehensive traineeguidance by a mentor and other investigators from both sites; (3) support through a scientific mentor group(the Individual Trainee Advisory Committee) comprised of investigators from both sites with expertise in eachtrainee's area of interest; (4) multi-disciplinary research courses and on-going training activities such as theMultidisciplinary Cancer Seminar Series and Lymphoma Group meetings at both sites; (5) encouragement ofcollaboration with Investigator Group meetings at both sites; (6) encouragement of collaboration withinvestigators at both Iowa and Mayo and (7) opportunities for research enhancement through theDevelopmental Research Program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA097274-06
Application #
7254605
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (J1))
Project Start
2007-07-01
Project End
2012-06-30
Budget Start
2007-08-17
Budget End
2008-06-30
Support Year
6
Fiscal Year
2007
Total Cost
$98,960
Indirect Cost
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Thompson, Carrie A; Yost, Kathleen J; Maurer, Matthew J et al. (2018) Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma. Hematol Oncol 36:749-756
Naik, Shruthi; Galyon, Gina D; Jenks, Nathan J et al. (2018) Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer. Mol Cancer Ther 17:316-326
Thanarajasingam, Gita; Maurer, Matthew J; Farooq, Umar et al. (2018) Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. Br J Haematol 183:149-152
Kleinstern, Geffen; Maurer, Matthew J; Liebow, Mark et al. (2018) History of autoimmune conditions and lymphoma prognosis. Blood Cancer J 8:73
Saad Aldin, Ehab; McNeely, Parren; Menda, Yusuf (2018) Posterior Reversible Encephalopathy Syndrome on 18F-FDG PET/CT in a Pediatric Patient With Burkitt's Lymphoma. Clin Nucl Med 43:195-198
Link, Brian K; Day, Bann-Mo; Zhou, Xiaolei et al. (2018) Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. Br J Haematol :
Ebeid, Kareem; Meng, Xiangbing; Thiel, Kristina W et al. (2018) Synthetically lethal nanoparticles for treatment of endometrial cancer. Nat Nanotechnol 13:72-81
Holahan, Heather M; Farah, Ronda S; Fitz, Sara et al. (2018) Health-related quality of life in patients with cutaneous T-cell lymphoma? Int J Dermatol 57:1314-1319
Maurer, Matthew J; Ghesquières, Hervé; Link, Brian K et al. (2018) Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. J Clin Oncol 36:1603-1610
Huet, Sarah; Tesson, Bruno; Jais, Jean-Philippe et al. (2018) A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncol 19:549-561

Showing the most recent 10 out of 387 publications